Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

HAE Stock - Haemonetics Corporation Stock Trading


home / stock / hae

HAE HAE Quote HAE Short HAE News HAE Articles HAE Message Board

MWN AI Summary *

Haemonetics Corporation (NYSE: HAE) is a global healthcare company specializing in blood management and blood component technologies. Founded in 1971 and headquartered in Braintree, Massachusetts, Haemonetics plays a critical role in the healthcare sector by providing innovative solutions that improve the safety and efficiency of blood donation and transfusion processes.

The company’s product portfolio includes a range of devices and software designed to optimize blood collection, processing, and transfusion protocols. Haemonetics is particularly known for its automated blood collection systems, such as its TEG® (thromboelastography) technology, which helps clinicians assess coagulation and monitor bleeding risks in real-time. Their offerings also encompass a range of consumables, software solutions, and services that support hospitals, blood centers, and healthcare providers in their operations.

Haemonetics operates primarily in four segments: Blood Center, Hospital, Cell Salvage, and International. The Blood Center segment is particularly significant as it serves the needs of blood banks and donation centers, enhancing the efficiency of blood collection processes. The Hospital segment, meanwhile, focuses on providing solutions that facilitate safe and effective transfusion practices. The company's commitment to research and development has established it as a leader in the field, fostering continuous innovation to meet changing healthcare demands.

In recent years, Haemonetics has demonstrated strong financial performance, driven by increasing demand for its products and a growing focus on patient safety and efficiency in healthcare. The firm has also pursued strategic acquisitions to enhance its technology portfolio and expand its global reach. As the healthcare landscape evolves, Haemonetics Corporation remains focused on delivering value-driven solutions to improve patient outcomes and streamline blood management processes, positioning itself for sustained growth in the coming years.

MWN AI Analysis *

Haemonetics Corporation (NYSE: HAE), a global leader in blood and plasma management solutions, presents a compelling investment opportunity as it approaches the end of 2023. The company has showcased strong performance in recent quarters, driven by an upsurge in demand for its innovative products amid increasing global awareness of the importance of blood and plasma donation.

Key factors enhancing Haemonetics' market position include its robust product portfolio, with offerings in blood collection, apheresis, and hemotherapy. The rise in chronic diseases necessitates advanced blood management solutions, positioning Haemonetics to benefit as healthcare providers look for efficient ways to enhance patient care.

Financial metrics reveal promising growth prospects. In recent earnings reports, Haemonetics has demonstrated consistent revenue growth, fueled by expanding international markets, particularly in emerging economies where healthcare infrastructure is improving. Analysts project strong revenue increases, with forecasts indicating a potential compound annual growth rate (CAGR) in the double digits over the next few years.

One concern, however, is the impact of macroeconomic factors such as inflation and supply chain disruptions that could affect operational costs. Investors should closely monitor the company’s ability to manage these challenges without compromising profitability. Additionally, Haemonetics' investment in R&D reflects its commitment to innovation, which is essential for maintaining competitive advantages while capturing new market segments.

In the current market environment, a diversified investment strategy may benefit investors looking to mitigate risk while gaining exposure to growth potential. Buying HAE at current levels could be advantageous, particularly if it dips on macroeconomic news. As the demand for blood and plasma management continues to grow, Haemonetics stands poised to capitalize on these trends, making it a stock worth considering for both growth-oriented and conservative investors.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Haemonetics Corporation (NYSE:HAE)

Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in three categories: Plasma, Blood Center and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, and anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood. Hospital, which is comprised of Hemostasis Management, Cell Salvage, Transfusion Management and Vascular Closure products, includes devices and methodologies for measuring coagulation characteristics of blood, surgical blood salvage systems, specialized blood cell processing systems and disposables, blood transfusion management software and vascular closure devices.

Quote | Haemonetics Corporation (NYSE:HAE)

Last:$73.45
Change Percent: 0.04%
Open:$74.38
Close:$73.45
High:$74.88
Low:$72.341
Volume:758,765
Last Trade Date Time:07/17/2025 03:41:44 pm

News | Haemonetics Corporation (NYSE:HAE)

  • XPH: Healthcare Dashboard For July

    2025-07-15 17:13:08 ET ... Read the full article on Seeking Alpha For further details see: XPH: Healthcare Dashboard For July

    • July 15, 2025 05:13:08 pm

    • |
    • SeekingAlpha
    • |
      • HAE Stock
      • HAE Quote
      • HAE Short
      • HAE News
      • HAE Articles
      • HAE Message Board
  • Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025 PR Newswire BOSTON , July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 fin...

    • July 09, 2025 04:05:00 pm

    • |
    • PR Newswire
    • |
      • HAE Stock
      • HAE Quote
      • HAE Short
      • HAE News
      • HAE Articles
      • HAE Message Board

Message Board Posts | Haemonetics Corporation (NYSE:HAE)

Subject By Source When
whytestocks: $HAE News Article - Haemonetics 2nd Quarter Fiscal Year 2023 Earnings Release Available whytestocks investorshangout 11/07/2022 9:00:52 PM
whytestocks: $HAE News Article - Haemonetics 3rd Quarter Fiscal Year 2022 Earnings Release Available whytestocks investorshangout 02/08/2022 3:10:48 PM
whytestocks: $HAE News Article - Trend Tracker for Haemonetics HAE whytestocks investorshangout 09/10/2021 7:00:49 PM
whytestocks: $HAE News Article - Haemonetics Corp (HAE) Q1 2022 Earnings Call Transcript whytestocks investorshangout 08/11/2021 3:50:49 PM
whytestocks: $HAE News Article - Haemonetics HAE Proactive Strategies whytestocks investorshangout 08/11/2021 3:35:47 PM

MWN AI FAQ **

What are the recent financial performance trends for Haemonetics Corporation (NYSE: HAE) in terms of revenue growth and profitability?

As of October 2023, Haemonetics Corporation (NYSE: HAE) has shown positive financial performance trends with steady revenue growth driven by strong demand for its blood management solutions, alongside improvements in profitability margins reflecting operational efficiencies.

How has Haemonetics Corporation HAE adapted its product offerings to meet the changing demands of the healthcare market?

Haemonetics Corporation has adapted its product offerings by innovating in blood management technologies, enhancing data analytics capabilities, and developing newer solutions for transfusion and surgical care to address the evolving needs of the healthcare market.

What are the key risks facing Haemonetics Corporation HAE in the current economic environment?

Key risks facing Haemonetics Corporation (HAE) in the current economic environment include supply chain disruptions, fluctuations in healthcare spending, increased competition in the medical device sector, regulatory challenges, and potential impacts from global economic uncertainties.

Can you provide insights into the competitive landscape for Haemonetics Corporation (NYSE: HAE) and its market positioning?

Haemonetics Corporation (NYSE: HAE) operates in a competitive landscape characterized by leading players in blood management solutions, with its focus on innovation and enhanced patient outcomes positioning it well against rivals while capitalizing on growing demand for blood products and services.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get HAE Alerts

News, Short Squeeze, Breakout and More Instantly...

Haemonetics Corporation Company Name:

HAE Stock Symbol:

NYSE Market:

0.04% G/L:

$73.45 Last:

758,765 Volume:

$74.38 Open:

$73.45 Close:

Haemonetics Corporation Website:

Haemonetics Corporation Logo

Ad

Investor Relations
RECENT HAE NEWS
  • HAE - Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025 PR Newswire BOSTON , July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 fin...

  • HAE - Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

    Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference PR Newswire BOSTON , May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will participate in a fireside chat with inv...

  • HAE - Expected US Company Earnings on Thursday, May 8th, 2025

    Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get HAE Alerts

Get HAE Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1